Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset
Cancer company Erasca is seeking a partner for its most advanced asset, a pan-RAF inhibitor being studied in a phase 3 melanoma study and a phase 1b solid tumor trial. The company is taking this direction in hopes of adding another year to its cash runway.
Cancer company Erasca is seeking a partner for its most advanced asset, a pan-RAF inhibitor being studied in a phase 3 melanoma study and a phase 1b solid tumor trial. The company is taking this direction in hopes of adding another year to its cash runway.
